367 related articles for article (PubMed ID: 25249654)
1. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
Salavati B; Rajji TK; Price R; Sun Y; Graff-Guerrero A; Daskalakis ZJ
Schizophr Bull; 2015 Jan; 41(1):44-56. PubMed ID: 25249654
[TBL] [Abstract][Full Text] [Related]
2. Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.
Egerton A; Modinos G; Ferrera D; McGuire P
Transl Psychiatry; 2017 Jun; 7(6):e1147. PubMed ID: 28585933
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical brain imaging investigations of schizophrenia.
Soares JC; Innis RB
Biol Psychiatry; 1999 Sep; 46(5):600-15. PubMed ID: 10472414
[TBL] [Abstract][Full Text] [Related]
4. Recent evidence for dopamine abnormalities in schizophrenia.
Abi-Dargham A
Eur Psychiatry; 2002 Aug; 17 Suppl 4():341s-347s. PubMed ID: 23573603
[TBL] [Abstract][Full Text] [Related]
5. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.
Frankle WG; Cho RY; Prasad KM; Mason NS; Paris J; Himes ML; Walker C; Lewis DA; Narendran R
Am J Psychiatry; 2015 Nov; 172(11):1148-59. PubMed ID: 26133962
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice.
Kortleven C; Fasano C; Thibault D; Lacaille JC; Trudeau LE
Eur J Neurosci; 2011 May; 33(10):1751-60. PubMed ID: 21410793
[TBL] [Abstract][Full Text] [Related]
7. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
8. The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
Reddy-Thootkur M; Kraguljac NV; Lahti AC
Schizophr Res; 2022 Nov; 249():74-84. PubMed ID: 32107102
[TBL] [Abstract][Full Text] [Related]
9. [Neuroimaging in schizophrenia].
Lanzenberger R; Kasper S
Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S51-9. PubMed ID: 16270245
[TBL] [Abstract][Full Text] [Related]
10. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
Lewis DA; Moghaddam B
Arch Neurol; 2006 Oct; 63(10):1372-6. PubMed ID: 17030651
[TBL] [Abstract][Full Text] [Related]
11. Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia.
Falkenberg LE; Westerhausen R; Craven AR; Johnsen E; Kroken RA; L Berg EM; Specht K; Hugdahl K
Neuroimage Clin; 2014; 4():576-84. PubMed ID: 24749064
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.
Erritzoe D; Talbot P; Frankle WG; Abi-Dargham A
Neuroimaging Clin N Am; 2003 Nov; 13(4):817-32. PubMed ID: 15024964
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.
Tsai G; van Kammen DP; Chen S; Kelley ME; Grier A; Coyle JT
Biol Psychiatry; 1998 Oct; 44(8):667-74. PubMed ID: 9798069
[TBL] [Abstract][Full Text] [Related]
14. Neurochemical imaging in schizophrenia.
Urban N; Abi-Dargham A
Curr Top Behav Neurosci; 2010; 4():215-42. PubMed ID: 21312402
[TBL] [Abstract][Full Text] [Related]
15. [Background and findings of neuroimaging in schizophrenia: an update].
Cuevas-Esteban J; Campayo A; Gutiérrez-Galve L; Gracia-García P; López-Antón R
Rev Neurol; 2011 Jan; 52(1):27-36. PubMed ID: 21246491
[TBL] [Abstract][Full Text] [Related]
16. Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research.
Tse MT; Piantadosi PT; Floresco SB
Biol Psychiatry; 2015 Jun; 77(11):929-39. PubMed ID: 25442792
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
[TBL] [Abstract][Full Text] [Related]
18. The role of dopamine for the pathophysiology of schizophrenia.
Meisenzahl EM; Schmitt GJ; Scheuerecker J; Möller HJ
Int Rev Psychiatry; 2007 Aug; 19(4):337-45. PubMed ID: 17671867
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.
Moeller SJ; London ED; Northoff G
Neurosci Biobehav Rev; 2016 Feb; 61():35-52. PubMed ID: 26657968
[TBL] [Abstract][Full Text] [Related]
20. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.
Kegeles LS; Mao X; Stanford AD; Girgis R; Ojeil N; Xu X; Gil R; Slifstein M; Abi-Dargham A; Lisanby SH; Shungu DC
Arch Gen Psychiatry; 2012 May; 69(5):449-59. PubMed ID: 22213769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
